The Face of the Patent is not the Whole Story : Determining Effective Patent Life in the US. Anne Marie Clark, Ph.D. and Heidi Berven,, Ph.D., J.D.

Similar documents
eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search

Hatch-Waxman Litigation: The Fish & Richardson Differential. An Integrated Approach and Strategy

Case 1:16-cv JMS-DML Document 1 Filed 02/05/16 Page 1 of 10 PageID #: 1

KEVIN J. McGOUGH Attorney at Law; Registered Patent Attorney 81 Pondfield Road, Number 268 Bronxville, New York (914)

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) COMPLAINT. Nature of Action

ACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

ARE PATENTS REALLY LIMITED TO 20 YEARS? A CLOSER LOOK AT PHARMACEUTICALS. Melody Wirz. I. Introduction

AN OVERVIEW OF THE UNITED STATES PATENT SYSTEM

Patent Basics for Inventors, Entrepreneurs, and Start-ups

Raising the Stakes in Patent Cases

AN OVERVIEW OF THE UNITED STATES PATENT SYSTEM

The IP Landscape for Combination Products

Trans-Pacific Partnership Lost Important IP Provisions

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

Could a Patent Term Reduction Solve the Software Patent Problem? Brian J.

Research Collection. Comment on Henkel, J. and F. Jell "Alternative motives to file for patents: profiting from pendency and publication.

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF OHIO WESTERN DIVISION : : Plaintiff,

Recent Development in Patent Exhaustion in Japan Speech for CASRIP High-Tech Summit 25. July Intellectual Property High Court of Japan

Case 5:07-cv D Document 1 Filed 06/06/07 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA

5 th Annual Pharma IPR Conference 2016

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION. Plaintiff, Civil Action No. 3:14-cv-1877

24-25 September, 2014 Hotel Taj Banjara, Hyderabad

David C. Doyle PARTNER EDUCATION BAR ADMISSIONS PRACTICES

Chapter 5 The Fundamentals of the Patent System

Case 1:16-cv TWP-MPB Document 1 Filed 03/16/16 Page 1 of 19 PageID #: 1

MOVING FORWARD IN HATCH-WAXMAN LITIGATION GETTING YOUR GENERICS TO MARKET

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS

Intellectual Property

Pharmaceutical Patents and Evergreening. Jürgen Dressel Head of Global Patent Litigation Strategy, Novartis Pharma FICPI 2015, Cape Town, 14 Apr 2015

University joins Industry: IP Department. Georgina Marjanet Ferrer International, SA

PATENTS FOR CHEMICALS, PHARMACEUTICALS AND BIOTECHNOLOGY

Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry

The MHRD Chair on IPR National Law School of India University

Effective Utilization of Patent Searches in the Wake of the AIA Patent Reform Law. April 30, 2012

Evergreening A Controversial Issue in Pharma Milieu*

March 16, 2013: Are You Ready for the New Patent Regime?

The Objective Valuation of Non-Traded IP. Jonathan D. Putnam

Death from the Public Domain?

21 January Introduction. About AIPPI and AIPPI Australia. General comments

Litigators for Innovators

Patent Law: What Anesthesiologists Should Know

Outline 3/16/2018. Patent Basics for Inventors, Entrepreneurs, and Start-ups.

Where do patent measures fall short in the life sciences? Bhaven N. Sampat Columbia University and NBER July 28, 2017

Moving Targets. Liversidge v- Abbott Laboratories in the Patents County Court. Stuart Jackson Partner

Patents. What the Med Tech Innovator Needs to Know. William Durfee. Department of Mechanical Engineering University of Minnesota Minneapolis, USA

Patent Basics for Inventors, Entrepreneurs, and Start-ups. Ned Landrum Patent Training Advisor STEPP Program Manager

MPEP Breakdown Course

Patenting Software Technology Experiences with India & US

- Examining Opportunities for Georgia

EVERGREENING OF PATENT

Case 1:16-cv UNA Document 1 Filed 12/16/16 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

Patent Law. Prof. Roger Ford September 7, 2016 Class 3 Disclosure: Enablement. Schedule notes

ASIP News. In this Isuue. ASIP held a workshop on the occasion of the World IP Day 2016

IN THE MATTER OF THE COMPETITION ACT, R.S.C. 1985, c. C-34, as am.

Killing One Bird with Two Stones: Pharmaceutical Patents in the Wake of Pfizer v Apotex and KSR v Teleflex

DRAFTING THE APPLICATION FOR THE GRANT OF A PATENT OR UMC ΟΡΓΑΝΙΣΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗΣ ΙΔΙΟΚΤΗΣΙΑΣ

Patent Due Diligence

PTO Day December 5, 2005

Case 4:14-cv BRW Document 58 Filed 12/04/15 Page 1 of 13

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.

From Transparency to Quality: Bridging the Gap Between Access to Knowledge and Medicines

Tafas v. Dudas et al Doc. 253 Att. 12 Case 1:07-cv JCC-TRJ Document Filed 01/22/2008 Page 1 of 30 EXHIBIT 12. Dockets.Justia.

R. Cameron Garrison. Managing Partner

Carnegie Endowment for International Peace

Patent Purchase Information of Seller

THE AMERICA INVENTS ACT NEW POST-ISSUANCE PATENT OFFICE PROCEEDINGS

IP, STRATEGY, PROCEDURE, FTO Peter ten Haaft (PhD, Dutch and European Patent Attorney)

Recent Changes to the Patent Litigation Landscape and Predictions for the Future. June 12, 2018

Academic Technology Licensing & the America Invents Act

Intellectual Property

MORGAN STATE UNIVERSITY PROCEDURES ON PATENTS AND TECHNOLOGY TRANSFER APPROVED BY THE PRESIDENT NOVEMBER 2, 2015

Empirical Research on Invalidation Request of Invention Patent Infringement Cases in Shanghai

Statement of. Hon. General J. Mossinghoff Senior Counsel Oblon, Spivak, McClelland, Maier & Neustadt, P.C. before the

US Patent Litigation Trends in Cloud Computing IPlytics GmbH

International IP. Prof. Eric E. Johnson. General Principles

Practical Strategies for Managing Patent Rights for Biotechnology and Medical Device Companies

Lewis-Clark State College No Date 2/87 Rev. Policy and Procedures Manual Page 1 of 7

Key Strategies for Your IP Portfolio

OIM Squared, Inc. - Patent Portfolio Report

Case 1:14-cv AJS Document 1 Filed 08/21/14 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA

Firm Overview. The firm includes 25 professionals, including 19 lawyers and 6 patent agents and technical specialists, of whom 10 hold Ph.D. degrees.

Fall National SBIR/STTR Conference

Strategic use of patents: The case of patent trolls

The role of IP in economic development: the case of China

As a Patent and Trademark Resource Center (PTRC), the Pennsylvania State University Libraries has a mission to support both our students and the

Ryan N. Phelan. Tel

A conversation on Patent Quality

Forever Green? An Examination of Pharmaceutical Patent Extensions

Invalidity Challenges After KSR and Bilski

Derwent Innovation Legal Status: Predictive Data on Derwent Innovation

COURSE SCHEDULE

Larry R. Laycock. Education. Practice Focus. Attorney at Law Shareholder

TRIPS and Access to Medicines. WR Briefing

Patents An Introduction for Owners

Welcome to the Tuesday 17th June 2014

Post-Grant Review in Japan

UNITED STATES PATENT AND TRADEMARK OFFICE

First to Invent vs. First to File: The Impact of an Old Dilemma on the Future of Biotechnology and Pharmaceutical Discoveries

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

Transcription:

The Face of the Patent is not the Whole Story : Determining Effective Patent Life in the US Anne Marie Clark, Ph.D. and Heidi Berven,, Ph.D., J.D.

Interface Between Patent Term and Regulatory Exclusivity Hatch-Waxman Extension PTO FDA Patent Term Regulatory Exclusivity Effective Product Exclusivity

Factors Affecting Patent Life and Regulatory Exclusivities Patent Life GATT Certificates of Correction Terminal Disclaimers Maintenance Fees Patent Term Adjustment Interference Infringement Hatch-Waxman Extensions Regulatory Exclusivities New Chemical Entities Exclusivity Data Exclusivity Orphan Drug Exclusivity Pediatric Extensions Rx to OTC Switches ANDAs

GATT Patents filed prior to June 8, 1995 receive the greater of 17 years from grant or 20 years from first filing. US 5,856,336 expires January 5, 2016 Jan. 5, 1999 May 25, 1992 January 5, 2016 Aug. 19, 1988

Certificate of Correction US 5,565,447 Expiration date calculated from the face of the patent March 28, 2014 not October 15, 2013 There is a Certificate of Correction First filing date

Certificate of Correction Caution: legal status databases will state there is a certificate of correction but will not provide additional information Corrected date of first filing Corrected patent expiry date October 15, 2013 But a request for extension has been filed so it may change again!! July 19, 1993 You must look at the certificate of correction!

Terminal Disclaimers All or a portion of a patent term can be disclaimed. A patent will have the term of a reference patent. Reference patent is not identified on patent face. Start by checking the patent family. US 5,917,007 is a divisional of US 5,679,717 Strategy not always successful.

Terminal Disclaimers US 5,679,717 has a terminal disclaimer and a certificate of correction. When does US 5,917,007 expire? Probably on April 29, 2014. You need the file- wrapper to confirm the patent term June 10, 2014 Apr. 29, 2014

Maintenance Fees Payment of maintenance fees is necessary to prevent patent expiration Must be paid on or before due date or within six months grace period. Can be paid after grace period if unintentional (within 24 months) or unavoidable (any time).

Maintenance Fees Use caution when stating patents have expired due to failure to pay maintenance fees. US 5,104, 361 expired May 14, 2003 for failure to pay maintenance fees. Revival possible US 4,875, 623 reinstated due to acceptance of late maintenance fees.

Patent Term Adjustment Caution: Legal Status Databases Are Incomplete American Inventors Protection Act Recover term if more than three year pendency Complex calculation PTA is on the face of the patent and PAIR 18 days

Interference Two inventors claim the same invention. Who was the first to invent? Determines the patent right. Claims can be lost due to an interference Caution: not covered by all legal status databases and not on front page of patent Does the patent still claim the item of interest? What patent has those claims? US 6,323,489 lost claims 1-101 10 due to an adverse judgment in an interference

Infringement All or part of patent can be lost in litigation Caution: not covered by all legal status databases and not on front page of patent US 5,573,780 the patents in the suit are invalid. Judgment is entered in favor of defendant, Merck & Company, and against plaintiff, Apotex Corp.

Interface Between Patent Term and Regulatory Exclusivity Hatch-Waxman Extension PTO FDA Patent Term Regulatory Exclusivity Effective Product Exclusivity

Hatch-Waxman Extensions Allows recovery of part of the time spent for FDA approval Up to 5 years extension subject to 14 year cap post approval 14 year rule not consistently covered by legal status databases or certificates of extension Information is not on the patent front page Orange book has errors and omissions

Hatch-Waxman Extensions In this case, the patent term expires on February 21, 2006 instead of July 14, 2007 (September 17, 2004 + 1030 days) because of the 14 year rule Caution: Check USPTO website www.uspto.gov for patent term extensions

New Chemical Entity (NCE) Exclusivity May Exceed Patent Term NCE market exclusivity for five years Fondaparinux Sodium Patent expires August 19, 2003 NCE market exclusivity expires December 7, 2006 Caution: Market exclusivity data is not available in patent legal status databases

Data Exclusivity (DE) May Exceed Patent Term DE for 3 years Caution: not in legal status databases Fluoxetine Hydrochloride Product Patent US 4,314,081 expired (it had both Hatch-Waxman and Pediatric exclusivity) New Dosage Form exclusivity until February 26, 2004

Orphan Drug Exclusivity (ODE) May Exceed Patent Term ODE for 7 years Anagrelide Hydrochloride Patent US Re. 31,617 expired on January 13, 1993, ODE until March 12, 2004 Orphan Drug exclusivity information is not available in patent legal status databases.

Pediatric Extensions Adds 6 months to each patent listed in the Orange Book. Pediatric extensions are not in legal status databases Alendronate Sodium Each patent is extended 6 months by pediatric exclusivity. Including US 4,621,077 that has a 1,371 day extension

to OTC switches If additional clinical trials are required for Rx to OTC switch, three years market exclusivity maybe granted Prevents generic OTC versions of product from being launched Omeprazole approved for OTC and granted three years market exclusivity Caution: not in legal status databases

ANDA 180 day exclusivity First generic to file paragraph IV certification entitled to 180 day exclusivity Moexipril Teva summary judgement of non- infringement of a US patent (US 4,743,450) Caution: not in legal status databases

Conclusion You cannot just look at the front page and determine the patent expiration date You should always look at the front page of a patent to cross-check check your search results Databases have limitations and omissions